38results about How to "Lessen lung damage" patented technology

Provided is a novel vaccine for preventing COVID-19, the nucleotide sequence of an antigen of the novel vaccine is SEQ NO: 1, the amino acid sequence of the antigen of the novel vaccine is SEQ NO: 2,and the antigen of the vaccine comprises two functional parts: an S protein receptor binding structural domain capable of inducing a specific neutralizing antibody and a T cell related N protein truncated peptide fragment capable of inducing and activating effector T cells; The vaccine disclosed by the invention has the characteristics that the T cell related N protein truncated peptide fragment has weak capability of inducing the generation of the N protein antibody, so that a vaccine inoculator and a COVID-19 infected patient can be identified by using the N protein antibody, and the vaccineantigen does not induce the generation of the N protein antibody, so that lung injuries can be reduced, and the vaccine is safer. The cell vaccine disclosed by the invention is low in manufacturing cost, and can induce generation of virus-specific neutralizing antibodies and T cell immune response.

We disclose a new and useful biomarker for acute kidney injury (i.e., AKI), renal ischemia reperfusion injury (i.e., IRI), ischemic acute kidney injury, and / or ischemic acute tubular necrosis (i.e., ATN). The biomarker is GRO-alpha (i.e., CXCL1, chemokine C-X-C ligand 1, GRO1, GROa, MGSA, MGSA alpha, MGSA-a, NAP-3, SCYB1). We detected the biomarker using a QUANTIKINE® human GRO-alpha immunoassay (Cat. No. DGR00, R & D Systems, Minneapolis, Minn.). In addition, we disclose a method of treating lung damage.

Methods for the reversal of hemorrhagic shock or hemorrhagic trauma.

Methods for the reversal of hemorrhagic shock or hemorrhagic trauma.

The invention concerns the use of a bombesin / gastrin releasing peptide antagonist in the treatment of inflammatory and immune-mediated inflammatory conditions, in particular sepsis, acute lung injury and rheumatoid arthritis as well as for the treatment or prophylaxis of brain disorders, preferably bipolar disorder, and in particular the different forms and / or subforms of bipolar disorder, such as mania, acute mania, severe mania, hypomania, depression, moderate depression, dysthymia, severe depression, episodes of mania and / or depression, psychosis / psychotic symptoms (e.g. hallucinations, delusions), mixed bipolar state, bipolar I disorder, bipolar II disorder and / or rapid-cycling bipolar disorder. In particular, specific nonapeptides with antagonist properties against bombesin or bombesin-like peptides, such as the gastrin releasing peptide, may be used in the treatment of inflammatory and immune-mediated inflammatory conditions as well as brain disorders.

The invention belongs to the technical field of biological medicines, and discloses application of intervening BOK in preparation of a medicine for treating novel coronavirus pneumonia. In order to find a new immunotherapy scheme for comprehensive treatment of novel coronavirus pneumonia, the research on the lung tissue of novel coronavirus pneumonia patients finds that the expression quantity of BOK in the lung tissue cell of the novel coronavirus pneumonia patients is increased, BOK gene knockout can inhibit the apoptosis of human lung cells and vascular endothelial cells induced by a novel coronavirus membrane protein, and BOK knockdown by injecting lentivirus into the trachea of a mouse to express shRNA (short hairpin Ribonucleic Acid) aiming at BOK can inhibit the apoptosis of the lung tissue induced by the novel coronavirus membrane protein, which indicates that BOK is expected to be applied to the comprehensive treatment of the novel coronavirus pneumonia and is prepared into the form of a medicine for treating the novel coronavirus pneumonia, which can relieve lung injury and alveolar cavity fluid infiltration of the novel coronavirus pneumonia patients, and is suitable for protecting lung tissues and organs in the novel coronavirus pneumonia process.

One embodiment of the present invention is directed toward methods for inhibiting the oxidation of lipids, proteins, and other compounds. Another embodiment is directed toward methods for treating conditions associated with microbial contamination, colonization, and / or infection.

The invention discloses an application of medical ozone in preparation of a medicine or preparation for inhibiting or treating sepsis complications caused by human infectious coronavirus, particularlynoval coronavirus 2019, and belongs to the field of biomedicines. According to the invention, medical ozone is used for actively inducing an endogenous anti-inflammatory mechanism to relieve sepsis lung injury, namely, ALI is treated without being limited by a certain single target point on a regulation and control membrane and a related single mechanism of the target, but the ALI is relieved from immunoregulation by actively inducing SOCS3 expression through AMPK to inhibit TLR4-p38-TF / MMP-9. The invention provides a brand-new thought and an excellent target for researching and developing anew anti-ALI drug.

The invention relates to the technical field of medical equipment, and discloses a respirator and a using method thereof. The respirator comprises an expiration flow sensor, an air supply flow sensorand a plurality of pressure sensors, a central processing unit, pressure adjusting equipment, an air supply gun and an exhalation valve, wherein the pressure sensors are used for measuring the air supply flow pressure and the expiration flow pressure and arranged on an air supply pipe and an expiration pipe; the central processing unit is used for receiving the data of the air supply flow sensor and the expiration flow sensor, comparing, integrating and calculating the data of the air supply flow and the expiration flow, and controlling the pressure adjusting equipment according to the integrated and calculated data and the data of the plurality of pressure sensors; the pressure adjusting equipment is used for adjusting the pressure of the air supply flow according to an instruction of thecentral processing unit and adjusting the pressure of the air supply flow; the air supply gun is used for conveying airflow with corresponding pressure according to data of the pressure adjusting equipment; and the exhalation valve is used for controlling and exhausting exhalation air flow. According to the respirator and the using method, the treatment success rate of the ARDS patient can be increased.

Compounds that inhibit p38α MAPK protein, and methods of using the same, are provided for treating or preventing diseases such as cancer or inflammatory diseases.

The invention belongs to the field of medicine preparation, and in particular relates to an application of simvastatin in preparing a drug for preventing pulmonary oxygen toxicity caused by high partial pressure oxygen. Simvastatin is dissolved in normal saline to prepare a 0.5-2mg / mL injection to use. The intraperitoneal injected dose of simvastatin is 5-20mg / Kg / d, and the drug is used once a day three days before being exposed to high partial pressure oxygen. Experiments verify that simvastatin can obviously reduce pulmonary permeability caused by high partial pressure oxygen, reduce the protein level in pulmonary edema and bronchoalveolar lavage fluid, alleviate lung inflammation and reduce the proportion of lung apoptosis so as to alleviate lung damage caused by pulmonary oxygen toxicity. Moreover, the application provided by the invention provides experimental data of more reasonably applying simvastatin to prevent pulmonary oxygen toxicity caused by high partial pressure oxygen clinically.